Arcutis Biotherapeutics financials
$26.75−2.12%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $129.9M | $105.4M | $129.5M | $99.2M | $81.5M | $65.8M | $71.4M | $44.8M | $30.9M | $49.6M | $13.5M | $38.1M |
| Gross profit | $118.9M | $95.6M | $117.8M | $90.5M | $74.0M | $57.0M | $64.5M | $39.3M | $27.4M | $46.3M | $11.3M | $36.9M |
| Gross margin | 91.6% | 90.7% | 91.0% | 91.2% | 90.8% | 86.6% | 90.3% | 87.7% | 88.8% | 93.4% | 83.4% | 96.9% |
| Operating income | $16.4M | -$9.1M | $18.4M | $8.5M | -$14.6M | -$24.5M | -$7.6M | -$39.1M | -$50.1M | -$31.6M | -$61.2M | -$36.9M |
| Net income | $15.0M | -$11.3M | $17.4M | $7.4M | -$15.9M | -$25.1M | -$10.8M | -$41.5M | -$52.3M | -$35.4M | -$66.3M | -$44.8M |
| Net margin | 11.6% | −10.7% | 13.4% | 7.5% | −19.5% | −38.1% | −15.1% | −92.8% | −169.6% | −71.4% | −490.0% | −117.5% |
| Diluted EPS | $0.11 | $-0.09 | $0.14 | $0.06 | $-0.13 | $-0.20 | $-0.09 | $-0.33 | $-0.42 | $-0.32 | $-0.71 | $-0.73 |
| EBITDA | $15.9M | -$8.5M | $14.3M | $9.1M | -$17.6M | -$21.6M | -$9.3M | -$37.8M | -$50.1M | -$31.3M | -$61.2M | -$36.5M |
| Operating cash flow | $12.6M | $2.2M | $26.2M | -$1.8M | $324.0K | -$30.4M | -$748.0K | -$34.7M | -$45.1M | -$31.6M | -$56.2M | -$44.0M |
| Free cash flow | $12.5M | $2.2M | $26.2M | -$1.8M | $246.0K | -$31.0M | -$748.0K | -$34.8M | -$45.1M | -$31.6M | -$56.3M | -$44.0M |
| Diluted shares | 135.9M | 129.4M | 123.0M | 132.9M | 127.0M | 126.0M | 125.0M | 124.3M | 123.5M | 111.0M | 92.9M | 61.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $34.1M | $34.8M | $42.9M | $47.1M | $72.7M | $53.1M |
| Short-term investments | $204.4M | $189.2M | $178.1M | $143.9M | $118.1M | $145.0M |
| Total debt | $108.9M | $109.4M | $109.0M | $108.5M | $108.0M | $107.6M |
| Total assets | $488.5M | $460.0M | $433.0M | $371.0M | $352.4M | $344.1M |
| Total liabilities | $268.0M | $270.4M | $243.5M | $212.9M | $213.5M | $201.4M |
| Shareholders' equity | $220.6M | $189.6M | $189.5M | $158.1M | $139.0M | $142.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology